Facebook
Twitter
LinkedIn
Forward
7th Annual Updates from ASH 2021: Practice Changing Abstracts
February 18, 2022
Our goal is to join community-based providers and academic oncologists to improve the care and outcomes of patients with hematologic malignancies. To reach this goal, this activity will address early treatment options and medical advances that can be implemented to reduce cancer-related deaths. Our overarching goal is to keep all healthcare professionals involved in the care of patients with hematologic malignancies to stay abreast of the latest scientific updates, innovative ideas, and timeliest issues related to their care. This conference will provide the target audience with information that can help improve patient management and care strategies. Participants will discuss with content experts rapidly evolving developments, discover new treatments for patients, and improve overall practice paradigms. We will educate and empower community-based oncologists on best practices for treating hematologic cancers and inform them of the indicators for when to refer a patient for tertiary level care.
Learn more at the conference website!
Target Audience
This activity is designed for primary care physicians, hematologists, pathologists, medical oncologists, resident and fellow trainees, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare professionals dedicated to the treatment of hematologic cancers.
Learning Objectives
At the conclusion of this activity, participants will be able to:
- Illustrate how cutting-edge data presented at the 2021 Annual Meeting of the American Society of Hematology (ASH) can apply to clinical practice, addressing best practices and guidelines;
- State the emerging treatment strategies for patients with low- and high-risk myeloid malignancies;
- Discuss the optimal patient selection, timing, and regimen for transplant;
- Evaluate clinical trial data in the context of cellular CAR T-cell therapy and its place in evolving hematologic malignancy treatment standards;
- Choose the optimal treatment, sequencing, and supportive care strategies for patients with lymphoma using evidence-based guidelines;
- Identify methods for integrating therapeutic advances such as CAR-T therapies idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) into practice for myeloma patient care;
- Describe the pathogenesis, diagnostic evaluation and therapeutic modalities available for common benign hematologic diseases and COVID-associated hematologic diseases.
*Agenda subject to change.
Virtual Conference
Chicago, IL
United States
WANT TO KNOW MORE?
Learn more about the conference by visiting the conference website!
ACCESSIBILITY The University of Chicago is committed to providing equal access appropriate to need and circumstances and complies fully with legal requirements of the Americans with Disabilities Act. If you are in need of special accommodation, please contact Meeting Achievements via e-mail via at support@meetingachievements.com.
The University of Chicago reserves the right to cancel or postpone this conference due to unforeseen circumstances. In the unlikely event this activity must be cancelled or postponed, the registration fee will be refunded; however, The University of Chicago is not responsible for any related costs, charges, or expenses to participants, including fees assessed by airline/travel/lodging agencies.
COURSE DIRECTOR
University of Chicago
KEYNOTE SPEAKER
Joseph Mikhael, MD, MEd, FRCPC, FACPProfessor, Applied Cancer Research and Drug Discovery Division
Translational Genomics Research Institute
UNIVERSITY OF CHICAGO PLANNING COMMITTEE
| Luca Capicchinoi, MSL Assistant Director, Cancer Services Administrator, Jonas Center for Cellular Therapy | Mylove Mortel, MSPH, RN, OCN Assistant Director, Transplant & Cell Therapy Clinical Operations |
| Ardrzej Jakubowiak, MD Professor of Medicine Director, Myeloma Program | Toyosi Odenike, MD Professor of Medicine Director, Leukemia Program |
| Justin Kline, MD Associate Professor of Medicine Director, Lymphoma Program | Sonali Smith, MD Elwood V. Jensen Professor in Medicine Chief, Sections of Hematology/Oncology |
| Ajay Major, MD Fellow, Hematology/Oncology |
UNIVERSITY OF CHICAGO FACULTY
Benjamin A. Derman, MD Assistant Professor of Medicine | Hongtao Liu, MD, PhD Associate Professor of Medicine |
Adam Duvall, MD, MPH Assistant Professor of Medicine | Mariam Nawas, MD Assistant Professor of Medicine |
Satyajit Kosuri, MD Assistant Professor of Medicine | Peter A. Riedell, MD Assistant Professor of Medicine |
Disclosure Declarations
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
Physician Credit
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 5.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Credit
University of Chicago Medicine is approved as a provider of nursing continuing professional development by the Ohio Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. (OBN-001-91)
This live activity is designated for a maximum of 5.25 continuing nursing education units.
This live activity is designated for a maximum of 5.25 continuing nursing education units.
American Board of Internal Medicine MOC II Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
American Board of Pediatrics MOC Part II Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.25 MOC points in the American Board of Pediatrics's (ABP) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.25 MOC points in the American Board of Pediatrics's (ABP) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.
Other Healthcare Professional Credit
Other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
Other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
Please Note: The credit claiming process will close three months after the conference end date. Requests to claim credit after three months will be subject to additional fees.
VIRTUAL EXHIBIT OPPORTUNITIES AVAILABLE!
This conference offers a tremendous opportunity to highlight your company products, services, and achievements in front of a wide array of key decision makers. Increase your company profile by participating as an exhibitor at this exciting event.
We are pleased to provide virtual opportunities for organizations to advertise their products and services to conference attendees Whether you are live chatting with an attendee regarding the elements available on your exhibit page, connecting with physicians during one of the scheduled breaks, or gaining brand recognition for your company through program acknowledgements, your message will reach physicians, hematologists, pathologists, medical oncologists, residents and fellows in training, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare professionals dedicated to the treatment of hematologic cancers.
Download the prospectus 
here or contact Meeting Achievements at support@meetingachievements.com or (219) 465-1115. We hope to see you there!
here or contact Meeting Achievements at support@meetingachievements.com or (219) 465-1115. We hope to see you there!
REGISTRATION
Click the button below to register. Early registration rates expire January 18, 2022, so don't delay!
Profession Type | In Person | Virtual |
|---|---|---|
Physicians | $75/$100 | $30/$40 |
Nurses, Pharmacists, Other Healthcare Professionals | $35/$50 | $20/$30 |
Residents & Fellows with verification letter | $25 | $25 |
| Industry | $395 | $195 |
CANCELLATION POLICY Please see the registration site for the full details. | ||
JOINING THE VIRTUAL CONFERENCE
Log in below using the instructions provided by Meeting Achievements via the e-mail used at registration. Onsite/Day of registrants, please allow 10-15 minutes post-registration for access information to be generated.
If you need assistance joining the session or experience other technical issues, contact technical support.
If you need assistance joining the session or experience other technical issues, contact technical support.
CLAIMING CREDIT
After creating an account or logging in, enter the access code to unlock the credit claiming process.
Please Note: The credit claiming process will close three months after the conference end date. Requests to claim credit after three months will be subject to additional fees.
Please login or create an account to proceed.